Flowchart for the Amyloid Imaging to Prevent Alzheimer’s Disease Diagnostic and Patient Management Study (AMYPAD-DPMS)
comorbidity, death
Reasons for not undergoing the baseline or 3-month visit included the following: incident comorbidity (n = 6), concerns about radiation exposure (n = 5), emigration (n = 4), COVID-19 lockdown (n = 3), insufficient cost/benefit ratio (n = 3), managing physician’s advice (n = 3), death (n = 2), inability to understand the study design (n = 1), and participation in a competing clinical trial (n = 1), while the remaining participants (n = 18) did not give any explanation. ITT indicates intention to treat; PET, positron emission tomography; PP, per protocol.At baseline, 785 of 794 participants (99%) underwent structural imaging (ie, MRI or CT), and 788 of 794 (99%) underwent cognitive screening (ie, Mini-Mental State Examination), with no difference among arms. The 